Pembrolizumab and Lenvatinib combination received a NICE recommendation for Endometrial Cancer

CAR-T Digest - August 2020

May 23, 2023: Pembrolizumab (IV) / Lenvatinib (IV) / Endometrial Cancer / Merck / Eisai: Received a NICE recommendation

NICE recommends Pembrolizumab + Lenvatinib for Endometrial Cancer in adults whose cancer has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or radiotherapy
This recommendation was based on the Phase 3 KEYNOTE-775 trial, data from this trial showed a median follow-up of 14.7 months
Efficacy data of this combination is quite encouraging with median progression-free survival of 7.3 months in comparison to chemo was 3.8 months
Additionally, median overall survival for the combination was 18.7 months in comparison to 11.9 months for chemo
In the experimental arm, 88.9% of patients had grade 3 or higher AEs, compared to 72.7% in the chemotherapy arm